Condition
Parkinson's Disease Clinical Trials
Studies of parkinson's disease, matched by condition name and medical subject headings. Start with those open to enrolment.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 967Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS).
- Trial name
- TroFuse-007 (NCT06170788)
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures
- Where
- 220 sites in United States, Argentina and 24 more
- Volunteers
- 614 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Researchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body.
- Trial name
- NCT06780085
- Testing
- Raludotatug Deruxtecan, Ifinatamab Deruxtecan, Docetetaxel
- Where
- 36 sites in United States, Chile and 8 more
- Volunteers
- 96 people
- Sponsor
- Merck Sharp & Dohme LLC
Overactive Bladder, Parkinson Disease
Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease
The purpose of this study is to learn about different treatments for overactive bladder symptoms in Parkinson's Disease. The investigators want to find out if people who do not respond to one treatment (either behavioral or drug…
- Trial name
- SQUARE PD (NCT07187466)
- Testing
- mirabegron, Exercise-based behavioral therapy
- Where
- 3 sites in United States
- Volunteers
- 146 people
- Sponsor
- VA Office of Research and Development
PARKINSON DISEASE (Disorder)
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
Vista PD is a randomized, placebo-controlled, multicenter study to evaluate the efficacy, PK, safety, and tolerability of VIM0423 in adults with Parkinson's disease tremor insufficiently responsive to dopaminergic therapy.
- Trial name
- Vista PD (NCT07804615)
- Testing
- VIM0423
- Where
- 30 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Vima Therapeutics
Parkinson Disease (PD), Type 1 Gaucher Disease
Parkinson's Disease in Type 1 Gaucher Disease
Parkinson's disease (PD) is an age-related movement disorder with a complex pathophysiology. Among the risk factors for PD, variants in beta-glucocerebrosidase (encoded by the gene GBA1) represent one of the most significant…
- Trial name
- NCT07886879
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Lysosomal Storage Disorders, Gaucher Disease
Genetic Studies of Lysosomal Storage Disorders
The purpose of this study is to identify genetic, biochemical, and clinical factors that are associated with disease severity in people with Gaucher disease and other lysosomal storage disorders.
- Conditions
- Lysosomal Storage Disorders, Gaucher Disease, Parkinson Disease
- Trial name
- NCT00001215
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Parkinson's Disease, Essential Tremor
Deep Brain Stimulation Surgery for Movement Disorders
Background: Deep brain stimulation (DBS) is an approved surgery for certain movement disorders, like Parkinson's disease, that do not respond well to other treatments.
- Conditions
- Parkinson's Disease, Essential Tremor, Dystonia
- Trial name
- NCT01581580
- Testing
- Medtronic Activa Tremor Control System, Deep Brain Stimulation
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Non-small Cell Lung Cancer
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat…
- Trial name
- NCT06345729
- Testing
- Calderasib, Pembrolizumab
- Where
- 246 sites in United States, Argentina and 28 more
- Volunteers
- 348 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
Genetics and Aerobic Exercise to Slow Parkinson's Disease Trial
The proposed multi-site, Genetics and Aerobic Exercise to Slow PD (GEARS) Trial will, for the first time, determine the interplay between genetics and exercise in altering PD progression.
- Trial name
- GEARS (NCT06442033)
- Testing
- High intensity stationary cycling
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Jay Alberts
Parkinson Disease
Lithium for Parkinson's: an Extension Trial
This study will examine the effects of 24 weeks of lithium therapy achieving serum lithium levels of 0.25-0.50mmol/L on MRI and blood-based biomarkers in Parkinson's disease patients who have completed one of our current 24-week…
- Trial name
- NCT06592014
- Testing
- Lithium aspartate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- State University of New York at Buffalo
Completed, with results posted
All 480Parkinson Disease
A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease
It is a phase II randomized, parallel, double-blind, placebo-controlled, multi-center clinical trial of the efficacy and safety of WD-1603 Carbidopa-Levodopa Extended-Release Tablets in patients with Parkinson's disease.
- Trial name
- NCT05036473
- Testing
- WD-1603 Carbidopa-Levodopa Extended-Release Tablets
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd.
Parkinson Disease, Depression
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease.
- Conditions
- Parkinson Disease, Depression, Anxiety
- Trial name
- PDP1 (NCT04932434)
- Testing
- Psilocybin therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Joshua Woolley, MD, PhD
Parkinson's Disease
Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease
The purpose of this study is to select the safest and most effective number of repeat doses of allogeneic bone marrow-derived mesenchymal stem cell (MSC) infusions to slow the progression of Parkinson's disease (PD).
- Trial name
- NCT04506073
- Testing
- Mesenchymal Stem Cells
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mya Schiess
Gait Disorders, Neurologic, Parkinson Disease
Bracing for Walking in Parkinson's Disease
Parkinson disease (PD) is a progressive neurological disease that results in characteristic gait dysfunction. Gait problems include decreased velocity, decreased stride length, difficulty with initiation of gait, postural…
- Trial name
- NCT03192046
- Testing
- Carbon Fiber Ankle Foot Orthosis (AFO), Standardized walking/exercise program
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Texas Southwestern Medical Center
Parkinson's Disease
ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease
This is primarily a safety protocol to evaluate the safety of subthalamotomy using Transcranial ExAblate for treatment of Parkinson's Disease (PD) motor features.
- Trial name
- NCT02246374
- Testing
- ExAblate Transcranial System
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- InSightec